Clinical Trials Directory

Trials / Completed

CompletedNCT01400100

Effects of Intraarterial Octreotide on Pancreatic Texture

Changes in Pancreatic Texture After Single-shot Administration of 500 µg Octreotide in the Gastroduodenal Artery During Pancreatoduodenectomy - a Double-Blinded Randomized Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
26 (actual)
Sponsor
St. Josef Hospital Bochum · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

The aim of the study is to test the hypothesis that intraarterial bolus application of 500 µg Octreotide in the gastroduodenal artery during the resectional phase of pancreatoduodenectomy in patients with soft pancreatic tissue hardens the texture of the pancreatic remnant. A primary end-point of the study is a change in pancreatic texture. A secondary end-point is the rate of postoperative pancreatic fistula.

Detailed description

Soft pancreas is an established risk factor for the development of postoperative pancreatic fistula in patients undergoing pancreatoduodenectomy. Octreotide is believed to harden the pancreas. This theory is based on the results of a single animal experiment and a small case series in humans. This hardening effect of octreotide has not quantitatively been proven in humans and its mechanism is not clear. Histomorphologic correlates of pancreatic hardness are unknown. In this study all patients who are eligible for pancreatoduodenectomy and sign the informed consent for participation in the study will be recruited. Those of them who prove to have a soft pancreas intraoperatively will receive a single bolus of 500 µg Octreotide in the gastroduodenal artery after its proximal division. Pancreatic hardness in the region of the resection margin will be quantitatively assessed by a Shore durometer before the intervention and at several time-points after it. The suture-holding capacity of pancreatic tissue at the resection margin will be quantitatively assessed by a dynamometer. Histomorphological features of pancreatic tissue will be characterized in details at the Institute of Pathology in order to define possible correlates of pancreatic hardness.

Conditions

Interventions

TypeNameDescription
DRUGIntraarterial application of Octreotide500 µg / 5 ml Octreotide is given as a single bolus injection in the gastroduodenal artery intraoperatively.
DRUGsterile NaCl (sodium chloride) 0,9% solutiona single intraarterial shot of 5 ml saline solution in the gastroduodenal artery

Timeline

Start date
2011-08-01
Primary completion
2012-02-01
Completion
2012-03-01
First posted
2011-07-22
Last updated
2012-03-06

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT01400100. Inclusion in this directory is not an endorsement.